<DOC>
	<DOCNO>NCT00428389</DOCNO>
	<brief_summary>This study design evaluate safety tolerability switch donepezil initial dose 5cm^2 rivastigmine patch formulation patient probable Alzheimer 's Disease ( MMSE 10-24 ) . The study include 5-week , open-label , randomized period follow 20-week open-label extension period . Patients randomize either immediate switch donepezil rivastigmine patch formulation switch rivastigmine patch formulation follow 7-day withdrawal period .</brief_summary>
	<brief_title>Safety Switching From Donepezil Rivastigmine Patch Patients With Probable Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Be least 50 year age ; Have diagnosis probable Alzheimer 's Disease ; Have MMSE score &gt; = 10 &lt; = 24 ; Must caregiver able attend study visit ; Have receive continuous treatment donepezil least 6 month prior screen , receive stable dose 5 mg/day 10 mg/day least last 3 6 month . Have advance , severe , progressive , unstable disease type may interfere efficacy safety assessment put patient special risk ; Have history malignancy organ system , treat untreated , within past 5 year ; Have history within past year current diagnosis cerebrovascular disease ; Have current diagnosis severe unstable cardiovascular disease ; Have history myocardial infarction ( MI ) last six month ; Severe unstable respiratory condition ( e.g. , severe asthma , severe pulmonary ( lung ) disease ) ; Digestive problem related peptic ulcer ; Urinary obstruction current severe urinary tract infection ; Abnormal thyroid function test ; Low folate Vitamin B12 ; Have disability may prevent patient complete study requirement ; Have current diagnosis active skin lesion/disorder would prevent adhesion patch ; Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Dementia , Alzheimer 's , Rivastigmine , donepezil</keyword>
</DOC>